Calreticulin signals upstream of calcineurin and MEF2C in a critical Ca2+-dependent signaling cascade by Lynch, Jeffrey et al.
T
H
E
J
O
U
R
N
A
L
O
F
C
E
L
L
B
I
O
L
O
G
Y
 
©
 
 The Rockefeller University Press $8.00
The Journal of Cell Biology, Vol. 170, No. 1, July 4, 2005 37–47
http://www.jcb.org/cgi/doi/10.1083/jcb.200412156
 
JCB: ARTICLE
 
JCB 37
 
Calreticulin signals upstream of calcineurin 
and MEF2C in a critical Ca
 
2
 
 
 
-dependent 
signaling cascade
 
Jeffrey Lynch,
 
1
 
 Lei Guo,
 
3
 
 Pascal Gelebart,
 
1
 
 Kaari Chilibeck,
 
1
 
 Jian Xu,
 
4
 
 Jeffery D. Molkentin,
 
4
 
 Luis B. Agellon,
 
1,2
 
 
and Marek Michalak
 
1
 
1
 
Department of Biochemistry and 
 
2
 
Canadian Institutes of Health Research Group in the Molecular and Cell Biology of Lipids, University of Alberta, 
Edmonton, Alberta, Canada T6G 2H7
 
3
 
Hepatic Toxicology, National Center for Toxicological Research, Food and Drug Administration, Jefferson, AR 72079
 
4
 
Children’s Hospital Medical Center, Molecular Cardiovascular Biology, Cincinnati, OH 45229
 
e uncovered a new pathway of interplay
between calreticulin and myocyte-enhancer
factor (MEF) 2C, a cardiac-speciﬁc tran-
scription factor. We establish that calreticulin works up-
stream of calcineurin and MEF2C in a Ca
 
2
 
 
 
-dependent
signal transduction cascade that links the endoplasmic
reticulum and the nucleus during cardiac development. In
the absence of calreticulin, translocation of MEF2C to the
nucleus is compromised. This defect is reversed by calre-
ticulin itself or by a constitutively active form of calcineurin.
Furthermore, we show that expression of the calreticulin
W
 
gene itself is regulated by MEF2C in vitro and in vivo
and that, in turn, increased expression of calreticulin af-
fects MEF2C transcriptional activity. The present ﬁndings
provide a clear molecular explanation for the embryonic
lethality observed in calreticulin-deﬁcient mice and em-
phasize the importance of calreticulin in the early stages
of cardiac development. Our study illustrates the exist-
ence of a positive feedback mechanism that ensures an
adequate supply of releasable Ca
 
2
 
 
 
 is maintained within
the cell for activation of calcineurin and, subsequently, for
proper functioning of MEF2C.
 
Introduction
 
The ER plays a key role in many cellular processes, including
Ca
 
2
 
 
 
 storage and release, protein synthesis, folding, and post-
translational modification (Baumann and Walz, 2001). For ex-
ample, Ca
 
2
 
 
 
 release from the ER affects numerous cellular
functions including modulation of apoptosis, stress responses,
organogenesis, and transcriptional activity (Berridge et al.,
2003). Calreticulin (CRT) is a Ca
 
2
 
 
 
-binding chaperone of the
ER involved in Ca
 
2
 
 
 
 storage and modulation of intracellular
Ca
 
2
 
 
 
 homeostasis (Michalak et al., 2002). Deletion of the CRT
gene leads to embryonic lethality via impaired cardiac develop-
ment, which results from malformation of the ventricular wall
(Mesaeli et al., 1999). Immediately postpartum, the CRT gene
is down-regulated because elevated expression of CRT in the
postnatal heart leads to the development of arrhythmias
(bradycardia), sinus node depression, complete heart block,
and, eventually, death from heart failure (Nakamura et al.,
2001a). The expression of CRT is also altered in failing and hy-
pertrophic hearts (Meyer et al., 1995; Hasenfuss et al., 1997;
Tsutsui et al., 1997), indicating that this protein plays a role in
postnatal/adult cardiac pathology. Cardiomyocytes are derived
from the mesoderm and are produced in response to protein
factors, including bone morphogenetic proteins, which are se-
creted from adjacent endoderm (Srivastava and Olson, 2000).
These signals activate numerous transcription factors (Nkx2.5,
dHAND, eHAND, Sox-4, myocyte-enhancer factor [MEF] 2,
nuclear factor of activated T-cells [NF-AT], and GATA), sev-
eral of which may be Ca
 
2
 
 
 
 dependent, and play a critical role in
specific stages of vertebrate cardiac morphogenesis and hyper-
trophy (Srivastava and Olson, 2000; Chien and Olson, 2002).
To date, only a few target genes have been identified for many
of these transcription factors.
In CRT-deficient cells, inositol 1,4,5-trisphosphate (InsP
 
3
 
)-
dependent Ca
 
2
 
 
 
 release from the ER is inhibited (Nakamura et
al., 2001b), indicating that Ca
 
2
 
 
 
-dependent signaling pathways
might be affected in the absence of CRT. Remarkably, overex-
 
Correspondence to Marek Michalak: marek.michalak@ualberta.ca
Abbreviations used in this paper: CaMK, Ca
 
2
 
 
 
/calmodulin-dependent protein
kinase; CaN, calcineurin; CRT, calreticulin; CsA, cyclosporin A; E, embryonic
day; EMSA, electrophoretic mobility shift assay; HDAC, histone deacetylase;
InsP
 
3
 
, inositol 1,4,5-trisphosphate; MEF; myocyte-enhancer factor; NF-AT, nu-
clear factor of activated T-cells; NRS, nuclear retention signal.
The online version of this article includes supplemental material. 
JCB • VOLUME 170 • NUMBER 1 • 2005 38
 
pression of constitutively active calcineurin (activated CaN), a
Ca
 
2
 
 
 
/calmodulin-dependent protein phosphatase, reverses the
defect in cardiac development observed in CRT-deficient
mice and rescues them from embryonic lethality (Guo et al.,
2002). The molecular mechanisms responsible for this rescue
are not known and it remains to be determined how CRT, a pro-
tein resident in the ER, impacts cardiac development.
In this study, we sought to identify the molecular mecha-
nisms responsible for both the CRT-dependent embryonic le-
thality and its CaN-dependent rescue. We show that nuclear
translocation of MEF2C requires CRT-dependent activation of
CaN and this interplay between CRT and MEF2C is a major
factor in CRT-deficient embryonic lethality. We also show that
MEF2C is a potent activator of the CRT gene in a positive
feedback mechanism that ensures that an adequate supply of
releasable Ca
 
2
 
 
 
 is maintained within the cell for activation of
CaN and, consequently, for nuclear translocation of MEF2C.
This study identifies steps in a set of apparently critical interac-
tions among CRT, CaN, and MEF2C that occur in the early
stages of cardiac development.
 
Results
 
MEF2C localization and transcriptional 
activity are compromised in the absence 
of CRT
 
To identify the molecular changes associated with CRT defi-
ciency, we performed protein/DNA array analysis, which was
designed for the analysis of Ca
 
2
 
 
 
-dependent transcription factors.
To distinguish between transcription factors that are present or
absent in the nucleus of wild-type and 
 
crt
 
 
 
/
 
 
 
 cells, in both the
absence and presence of Ca
 
2
 
 
 
, nuclear fractions were isolated
from wild-type and 
 
crt
 
 
 
/
 
 
 
 cardiomyocytes, which had been
treated with a Ca
 
2
 
 
 
 ionophore. Initially, we tested for nuclear
localization of NF-AT. NF-AT was localized to the nucleus in
bradykinin-stimulated wild-type cells but was absent in the
 
crt
 
 
 
/
 
 
 
 cells (Mesaeli et al., 1999; Fig. 1 A). When Ca
 
2
 
 
 
 was
added to the 
 
crt
 
 
 
/
 
 
 
 cells, NF-AT was translocated to the nu-
cleus (Fig. 1 A) because of a Ca
 
2
 
 
 
-dependent activation of
CaN. Most importantly, nuclear extracts isolated from 
 
crt
 
 
 
/
 
 
 
cells did not contain MEF2C (Fig. 1 A). After treatment of
these cells with the Ca
 
2
 
 
 
 ionophore the nuclear extracts did
contain MEF2C (Fig. 1 A). In contrast, the nuclear localization
of GATA was unaffected by the presence or absence of CRT or
Ca
 
2
 
 
 
 (Fig. 1 A).
Next, we performed a histological analysis to compare
the localization of MEF2C in wild-type and 
 
crt
 
 
 
/
 
 
 
 embryonic
day (E) 12.5 embryonic hearts. In sections from the ventricles
of wild-type hearts, MEF2C was localized to the nucleus of the
cardiomyocytes (Fig. 1 B, a). In contrast, in sections from 
 
crt
 
 
 
/
 
 
 
embryos, MEF2C was localized predominantly in the cyto-
plasm (Fig. 1 B, b). To determine whether or not MEF2C is
functionally active in the absence of CRT, mRNA was isolated
from wild-type and 
 
crt
 
 
 
/
 
 
 
 cardiac tissue and then analyzed by
RT-PCR to assess the expression of MEF2C gene targets
(Morin et al., 2000). MLC2v, eHAND, and Irx4 mRNAs were
readily detected in cardiomyocytes from wild-type animals, but
not in those from 
 
crt
 
 
 
/
 
 
 
 animals (Fig. 1 C). Thus, we conclude
that the localization of MEF2C to the nucleus and its function
are both altered in the absence of CRT.
 
Ca
 
2
 
 
 
 and CaN restore the nuclear 
localization of MEF2C in 
 
crt
 
 
 
/
 
 
 
 cells
 
We investigated the roles of Ca
 
2
 
 
 
, CaN, and Ca
 
2
 
 
 
/calmodulin-
dependent protein kinase (CaMK) in the nuclear targeting of
MEF2C. In wild-type cells stimulated with bradykinin (Naka-
mura et al., 2001b), MEF2C was localized to the nucleus (Fig. 2
A, a), in keeping with our previous observations in ventricle wall
sections (Fig. 1 B, a). This localization was unaffected by Ca
 
2
 
 
 
or by the expression of activated CaN, activated CaMKII (Fig. 2
A, b–d), or activated CaMKI (Fig. S1, available at http://
www.jcb.org/cgi/content/full/jcb.200412156/DC1). The nuclear
import of MEF2C in 
 
crt
 
 
 
/
 
 
 
 cells stimulated with bradykinin was
also impaired and the majority of MEF2C was found in the cyto-
plasm (Fig. 2 A, e). Expression of recombinant CRT in 
 
crt
 
 
 
/
 
 
Figure 1. MEF2C is absent in the nuclei of crt
 /  cells. (A) Protein/DNA
array analysis of nuclear fractions isolated from wild-type and crt
 / 
cardiomyocytes. Four spots represent each individual transcription factor.
Genes on the array are spotted in duplicate with the bottom the two spots
representing a 1:10 dilution of the top spots. Top, wild-type cells; middle,
crt
 /  cells; bottom, crt
 /  cells treated with Ca
2  ionophore. (B) MEF2C
localization in sagittal sections of E12.5 heart ventricular walls. Sections
from wild-type (a) tissue had dark nuclear staining. In the crt
 /  (b) sections,
the staining was observed predominately in the cytoplasm. (C) Expression
of MEF2C-activated genes is repressed in hearts from crt
 /  mice. Lane 1,
no RNA; lane 2, wild-type cardiomyocytes; lane 3, crt
 /  cardiomyocytes.
The size of PCR products for MLC2v, eHand, Irx4, and GATA6 is 301,
415, 604, and 641 bp, respectively. 
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cells restored nuclear translocation of MEF2C (Fig. 2 A, i).
MEF2C was also found in the nucleus of 
 
crt
 
 
 
/
 
 
 
 cells after their
treatment with a Ca
 
2
 
 
 
 ionophore (Fig. 2 A, f). These observa-
tions indicate that the translocation of MEF2C into the nucleus
depends on increased concentrations of Ca
 
2
 
 
 
 in the cytoplasm.
We looked at possible roles for CaN and CaMKII in the
Ca
 
2
 
 
 
-dependent nuclear translocation of MEF2C. When we
transfected 
 
crt
 
 
 
/
 
 
 
 fibroblasts with an expression vector encod-
ing activated CaN, the nuclear translocation of MEF2C was
fully restored (Fig. 2 A, g). The expression of activated
CaMKII (Fig. 2 A, h) or activated CaMKI (Fig. S1) did not in-
crease translocation of MEF2C to the nucleus in 
 
crt
 
 
 
/
 
 
 
 cells.
The activated CaMKII expressed in these cells was functional,
even in the absence of CRT, as indicated by its ability to pro-
mote the nuclear export of GFP-histone deacetylase (HDAC)
5 (Fig. S2, available at http://www.jcb.org/cgi/content/full/
jcb.200412156/DC1; McKinsey et al., 2001).
Translocation of MEF2C to the nucleus was also inves-
tigated in wild-type and 
 
crt
 
 
 
/
 
 
 
 fibroblasts transfected with
expression vector encoding a GFP-MEF2C fusion protein.
GFP-MEF2C was localized in the nucleus of wild-type cells
and this was unaffected by Ca
 
2
 
 
 
, activated CaN, or activated
CaMKII (Fig. 2 B, a–d). In agreement with the immunostaining
analysis presented in Fig. 2 A, we found that GFP-MEF2C was
mainly located in the cytoplasm in 
 
crt
 
 
 
/
 
 
 
 cells (Fig. 2 B, e). We
noted that GFP-MEF2C exhibited some nuclear localization in
 
crt
 
 
 
/
 
 
 
 fibroblasts and cardiomyocytes (Fig. 2, B, D, and E).
Quantitative analysis of MEF2C cellular distribution revealed
that it was only detected in the nuclear fractions isolated from
wild-type cells and this localization was not affected by the
presence of activated CaN (Fig. 2 C). In 
 
crt
 
 
 
/
 
 
 
 cells the majority
of GFP-MEF2C was recovered in the cytoplasmic fraction with
a small quantity in the nuclear fraction (Fig. 2 C). The level of
nuclear GFP-MEF2C in 
 
crt
 
 
 
/
 
 
 
 cells varied from 15 to 38% (Fig.
2 C) of the total GFP-MEF2C. Importantly, in 
 
crt
 
 
 
/
 
 
 
 cells ex-
pressing activated CaN, GFP-MEF2C was translocated to the
nucleus and recovered only in the nuclear fraction (Fig. 2 C). It
was not clear why some GFP-MEF2C was found in the nucleus
Figure 2. Nuclear localization of MEF2C is impaired in
the absence of CRT. (A) Localization of MEF2C in brady-
kinin-stimulated wild-type cells (a), crt
 /  cells (e), and
crt
 / cells expressing recombinant CRT (crt
 /  CRT; i).
(b, f, and j) Cells were treated with Ca
2  ionophore.
(c, g, and k) Wild-type, crt
 / , and crt
 /  CRT cells
transfected with expression vector encoding activated
CaN. (d, h, and l) Cells transfected with activated
CaMKII expression vector. (B) Localization of GFP-
MEF2C in bradykinin-stimulated wild-type cells (a–d),
crt
 /  cells (e–h), and crt
 /  cells stably transfected with
CRT (i–l). (b, f, and j) Cells were treated with Ca
2  iono-
phore. (c, g, and k) Wild-type, crt
 / , and crt
 /  CRT
cells transfected with expression vector encoding acti-
vated CaN. (d, h, and l) Cells transfected with activated
CaMKII expression vector. (C) Wild-type and crt
 / 
mouse embryonic fibroblasts were transiently transfected
with expression plasmids for GFP-MEF2C and activated
CaN followed by Western blot analysis. wt, wild-type
cells. (D) Cardiomyocytes isolated from wild-type (a and c)
or crt
 /  (b and d) E12.5 embryos were cultured and
transfected with expression plasmids for GFP-MEF2C and
activated CaN. GFP-MEF2C was exclusively nuclear in
wild-type cells stimulated with bradykinin (a) or crt
 / 
cells expressing activated CaN (d), but not in crt
 / 
cells (b). (E) Wild-type mouse embryonic fibroblasts were
transfected with expression plasmids for GFP-MEF2C,
activated CaN (CaN*), activated CaMKI (CaMKI*), and
activated CaMKII (CaMKII*). Cells were treated with
0.1  M CsA (b–d) or 1  M KN62 (f–h).JCB • VOLUME 170 • NUMBER 1 • 2005 40
in crt
 /  cells but a limited mistargeting of GFP-MEF2C has
also been reported for skeletal muscle cells (Wu et al., 2000).
The expression of activated CaMKII (Fig. 2 B, h) had no effect
on the localization of GFP-MEF2C in crt
 /  cells; MEF2C re-
mained predominantly cytoplasmic. In crt
 /  cells expressing
recombinant CRT, the GFP-MEF2C was fully recovered in the
nucleus (Fig. 2 B, i) and it remained nuclear in the presence of
Ca
2  ions and in cells expressing activated CaN (Fig. 2 B, j and k).
Inefficient nuclear targeting of GFP-MEF2C was also seen in cul-
tured embryonic cardiomyocytes isolated from E12.5 wild-type
and crt
 /  embryos (Fig. 2 D, a and b) and some nuclear GFP-
MEF2C was also detected (Fig. 2 B, e and h). Importantly, the
expression of activated CaN in crt
 /  embryonic cardiomyocytes
restored the nuclear translocation of GFP-MEF2C (Fig. 2 D, d).
To further investigate the role of CaN in MEF2C nuclear
targeting, we examined MEF2C localization in wild-type cells
treated with cyclosporin A (CsA), a drug that blocks CaN ac-
tivity. In the presence of CsA, GFP-MEF2C was predomi-
nantly cytoplasmic and only a small fraction of GFP-MEF2C
was nuclear (Fig. 2 E). This was similar to GFP-MEF2C local-
ization in crt
 /  cells (Fig. 2 B) and it was in sharp contrast to
exclusively nuclear localization of GFP-MEF2C in wild-type
untreated cells. Expression of activated CaN, activated CaMKI,
or activated CaMKII had no effect on the GFP-MEF2C local-
ization in wild-type cells treated with CsA and the GFP-
MEF2C remained largely cytoplasmic (Fig. 2 E, b–d). We also
used a CaMK inhibitor, KN62, to further test if CaMK may
play any role. Inhibition of CaMK had no effect on nuclear lo-
calization of GFP-MEF2C and it remained nuclear in the pres-
ences of KN62 (Fig. 2 E, e–h). Together our DNA array and
immunolocalization data indicate that, in both fibroblasts and
cardiomyocytes, translocation of MEF2C to the nucleus is
compromised in the absence of CRT but is fully restored by in-
creased cytoplasmic Ca
2  concentration or by the activation of
CaN. These findings provide biochemical evidence that CRT
and CaN regulate cellular targeting and activity of MEF2C.
To investigate the specificity of the CRT/CaN-dependent
pathway for translocation of MEF2C, we examined whether
the nuclear localization of other muscle transcription factors
(GFP-MEF2A, GFP-MyoD, and GFP-GATA6) is affected by
the absence of CRT. GFP-MEF2A was localized to the nucleus
in both wild-type and crt
 /  fibroblasts (Fig. 3 A), and this was
unaffected by stimulation of cells with bradykinin (not de-
picted), changes in the intracellular Ca
2  concentration with
ionophore (Fig. 3 A, b), and expression of activated CaN (Fig.
3 A, c and g) or activated CaMKII (Fig. 3 A, d and h). GFP-
MyoD (Fig. 3 B, a and b) and GFP-GATA6 (Fig. 3 B, c and d)
were also localized to the nucleus in the crt
 /  fibroblasts. We
also found that GFP-HDAC5 was localized to the nucleus in
both wild-type and crt
 /  fibroblasts (Fig. S2). These data indi-
cate that the compromised nuclear localization of MEF2C seen
in crt
 /  cells is specific for this transcription factor.
A role of the COOH-terminal domain 
of MEF2C
We investigated whether the COOH-terminal region of MEF2C,
which contains a NLS and a nuclear retention signal (NRS;
Borghi et al., 2001), is responsible for Ca
2 - and CaN-depen-
dent nuclear targeting of MEF2C. The GFP fusion protein that
encompasses both the NRS and NLS (GFP-MEF2C-NRS-NLS;
Fig. 4 A) localized to the nucleus in bradykinin-stimulated
wild-type cells, and it remained there in the presence of Ca
2 ,
activated CaN, or activated CaMKII (Fig. 4 B, a–d). In con-
trast, it was mainly cytoplasmic in the stimulated crt
 /  cells
(Fig. 4 B, e) with a portion of the GFP fusion protein in the nu-
cleus, just as we have seen for full-length GFP-MEF2C (Fig. 2
B). The addition of a Ca
2  ionophore or the expression of acti-
vated CaN both resulted in translocation of the GFP-MEF2C-
NRS-NLS to the nucleus (Fig. 4 B, f and g), but the expression
of activated CaMKII had no effect (not depicted).
Next, we investigated the contribution of just the NLS re-
gion to the nuclear localization of MEF2C. GFP-MEF2C-NLS
was localized to the nucleus in the stimulated wild-type cells
(Fig. 4 C, a) and this was unaffected by Ca
2 , activated CaN, or
activated CaMKII (Fig. 4 C, b–d). However, GFP-MEF2C-
NLS failed to completely translocate to the nucleus in crt
 / 
cells (Fig. 4 C, e), and its full translocation was restored by
Figure 3. MEF2A, MyoD, and GATA6 in crt
 /  cells. (A) GFP-MEF2A was
nuclear in wild-type (a–d) and crt
 /  (e–h) cells and this was unaffected by
Ca
2  (b and f), activated CaN (c and g), or activated CaMKII (d and h).
(B) Wild-type and crt
 /  cells were transfected with expression plasmids
for GFP-MyoD (a and b) and GFP-GATA6 (c and d). The nuclear localiza-
tion of GFP-MyoD and GFP-GATA6 was not influenced by CRT and both
transcription factors remained nuclear in crt
 /  cells.CALRETICULIN AND CARDIAC DEVELOPMENT • LYNCH ET AL. 41
Ca
2  (Fig. 4 C, f) and by activated CaN (Fig. 4 C, g). Thus, the
COOH-terminal 30 amino acids of MEF2C are essential and
sufficient for its translocation to the nucleus, and they mediate
the Ca
2 - and CaN-dependent restoration of translocation that
is seen in the absence of CRT.
MEF2C is a target of CaN phosphatase 
activity
The NLS and NRS, which are located at the COOH-terminal of
MEF2C, are flanked by potential phosphorylation sites (Borghi
et al., 2001). To determine whether CaN affects the phosphory-
lation state of MEF2C, wild-type and crt
 / -expressing cells
GFP-MEF2C-NLS were stimulated with bradykinin followed
by treatment with CsA or treatment with a Ca
2  ionophore. Im-
munoblot analysis revealed expression of two distinct protein
bands: a lower mobility corresponding to hyperphosphorylated
GFP-MEF2C-NLS and a greater mobility representing dephos-
phorylated GFP-MEF2C-NLS (Fig. 4, D and E). The identity
of the hyperphosphorylated GFP-MEF2C-NLS was confirmed
by incubation of protein extracts with alkaline phosphatase
(Fig. 4, D and E). In the wild-type cells, the dephosphorylated
form of GFP-MEF2C-NLS was detected in cells stimulated
with bradykinin (Fig. 4 D), treated with Ca
2  ionophore (Fig.
4 D, lane 3), or expressing activated CaN (Fig. 4 D). Hy-
perphosphorylated GFP-MEF2C-NLS was only observed in
wild-type cells stimulated with CsA (Fig. 4 D, lane 2). In the
absence of CRT, the dephosphorylated form of GFP-MEF2C-
NLS was detected only in the presence of the Ca
2  ionophore
(Fig. 4 E, lane 3) or in conjunction with the expression of acti-
vated CaN (Fig. 4 E, lane 4). The requirement for active CaN
was confirmed in the cells treated with CsA (Fig. 4 E, lane 2).
CaN had no effect on the electrophoretic mobility of GFP alone
(unpublished data). We conclude that the COOH-terminal re-
gion of MEF2C, containing the NLS consensus sequence im-
portant for nuclear translocation of the protein, is a target for
Ca
2 -dependent dephosphorylation by CaN.
To identify a specific amino acid residue at the COOH
terminus of MEF2C that might play a role in CaN-dependent
nuclear translocation of MEF2C, we performed site-specific
mutation of threonine and serine residues located near the
MEF2C NLS. T409A, S412A, S418A, S420A, and T432A
MEF2C mutants were expressed in crt
 /  cells followed by lu-
ciferase reporter gene analysis (Fig. 4 F). In agreement with the
localization studies, wild-type MEF2C was fully active in
bradykinin-stimulated wild-type cells but not in stimulated
crt
 /  cells (Fig. 4 F). T409A, S418A, S420A, and T432A
mutants remain inactive in the absence of CRT (Fig. 4 F). In
contrast, mutation of Ser
412 to Ala produced transcriptionally
active MEF2C in crt
 /  cells (Fig. 4 F), indicating that Ser
412
played a role in Ca
2 - and CaN-dependent activation and nuclear
translocation of MEf2C.
The CRT gene is a target for MEF2C
Next, we investigated the possibility that MEF2C might acti-
vate the CRT gene during cardiogenesis. We cotransfected
NIH3T3 cells with an expression vector encoding MEF2C and
a vector containing the luciferase reporter gene controlled by
Figure 4. Ca
2 - and CaN-dependent dephosphorylation of MEF2C. (A)
Schematic diagrams of full-length MEF2C and GFP-MEF2C deletion mu-
tants. Red box, MEF2C domain; dark blue box, MADS box. The locations
of the NLS and NRS are indicated. (B) Localization of GFP-MEF2C-NRS-
NLS fusion protein in mouse embryonic fibroblasts. GFP-MEF2C-NRS-NLS
was nuclear in bradykinin-stimulated wild-type cells (a) and cytoplasmic in
stimulated crt
 /  cells (d). GFP-MEF2C-NRS-NLS was translocated to the
nucleus in crt
 /  cells, which had been treated with a Ca
2  ionophore (e),
and in cells expressing activated CaN (f). (C) GFP-MEF2C-NLS was local-
ized to the nuclei of stimulated wild-type cells (a–c), whereas it was
present predominantly in the cytoplasm of stimulated crt
 /  cells (d). In-
creased cytoplasmic Ca
2  concentrations (e) and the expression of activated
CaN (f) both resulted in translocation of GFP-MEF2C-NLS to the nucleus.
Activated CaMKII had no effect and the fusion protein remained cytoplas-
mic in crt
 /  cells. (D) Wild-type mouse embryonic fibroblasts were trans-
fected with an expression vector for GFP-MEF2C-NLS and stimulated with
bradykinin (lanes 1–3 and 5). Top and bottom protein bands correspond
to hyperphosphorylated (hyperGFP-MEF2C-NLS) and hypophosphorylated
(hypoGFP-MEF2C-NLS) GFP-MEF2C-NLS, respectively. (E) crt
 /  cells
were transfected with an expression vector for GFP-MEF2C-NLS and acti-
vated CaN followed by Western blot analysis as described in D. (D and
E) Lane 1, control; lane 2, cells treated with 0.25  M CsA; lane 3, cells
treated with Ca
2  ionophore; lane 4, cells expressing activated CaN;
lanes 5–8, protein extracts treated with AP (CIP). (F) wild-type and crt
 / 
cells were transiently cotransfected with the expression vectors encoding
MEF2C or MEF2C mutants. Cells were stimulated with bradykinin, har-
vested, and assayed for luciferase and  -galactosidase activity (luciferase/
 -galactosidase   891090   5 and 1358402   4% in wild-type and
crt
 /  cells, respectively). The data shown are the mean   SD of three
independent experiments.JCB • VOLUME 170 • NUMBER 1 • 2005 42
the CRT promoter. There was an induction of luciferase activ-
ity in bradykinin-stimulated NIH3T3 cells transfected with an
expression vector encoding MEF2C (Fig. 5 A). Although
Nkx2.5, myocardin, and GATA6 also activated the CRT pro-
moter, MEF2C had the strongest effect (Fig. 5 A). NF-ATc4
had no effect on the CRT promoter (Fig. 5 A). Cotransfection
of NIH3T3 cells with expression vectors encoding MEF2C and
other factors did not further increase transcriptional activation
of the CRT promoter (Fig. 5 A). This finding suggests that
MEF2C does not interact with other transcription factors when
it activates the CRT promoter.
Deletion analysis indicated that activation of the CRT
promoter by MEF2C occurs via a site located at  846 to
 837 (Fig. S3, available at http://www.jcb.org/cgi/content/full/
jcb.200412156/DC1). To determine whether MEF2C bound to
this element, we performed an electrophoretic mobility shift
assay (EMSA). In the EMSA, we used recombinant MEF2C
and 
32P-labeled synthetic deoxyoligonucleotides, which had ei-
ther a sequence matching the putative MEF2C binding region
on the CRT promoter (Fig. 5 B, probe 1) or a modified se-
quence (Fig. 5 B, probe 2). In the probe 2, the probe 1 sequence
was modified by replacing AA nucleotides with CT nucle-
otides to generate, potentially, a perfect MEF2C consensus
binding site (Fig. 5 B). MEF2C bound to probes 1 and 2 (Fig. 5
B, lanes 2 and 3) and this binding was competed out in the
presence of an excess of unlabeled probe 1 (Fig. 5 C, lanes 3–7).
We conclude that MEF2C binds to the identified site within the
CRT promoter.
To determine whether MEF2C interacts with the CRT
promoter in cells, we performed chromatin immunoprecipita-
tion (ChIP) analysis (Fig. 5 D). Mouse embryonic fibroblasts
(Fig. 5 D, left) and cultured cardiomyocytes (Fig. 5 D, right)
Figure 5. MEF2C activates the CRT promoter. (A)
NIH3T3 cells were transiently cotransfected with the ex-
pression plasmids indicated with a luciferase reporter
gene controlled by the CRT promoter. Cells were stimu-
lated with bradykinin before harvesting. Individual con-
trols were obtained for each expression plasmid and the
data were plotted relative to that of control (luciferase/
 -galactosidase   1634240   5%). The data shown are
the mean   SD of three independent experiments. (B)
EMSA analysis of MEF2C binding to the CRT promoter.
Luciferase protein was used as a negative control (lane
1). Lane 2, consensus MEF2C site (33-mer, probe 2);
lane 3, the putative MEF2C site within the CRT promoter
(33-mer probe 1). The positions of MEF2C–DNA com-
plexes are indicated. Nucleotide sequences of synthetic
oligodeoxynucleotides used for EMSA analysis are indi-
cated. MEF2C binding sequences are in bold and under-
lined. (C) EMSA of nonlabeled probe 1 competing for
binding to a putative MEF2C site on the CRT promoter.
Lanes 1 and 2, radiolabeled probes 1 and 2, respectively.
Lanes 3–7, radiolabeled probe 1 with increasing concen-
tration of unlabeled probe 1. The position of MEF2C–
DNA complexes is indicated. (D) ChIP analysis of a puta-
tive MEF2C binding site in the mouse CRT promoter. Lane
1, DNA standard; lane 2; control sample, a PCR-driven
amplification of a vector containing a 1,722-bp CRT pro-
moter with a putative MEF2C site (E); lane 3; ChIP analy-
sis of cells transfected with control pcDNA3.1 vector;
lane 4, PCR-driven analysis of cells transfected with His-
tag MEF2C expression vector. A 340-bp PCR product of
the CRT promoter containing an MEF2C site is present in
the control (lane 2) and in cells transfected with the
MEF2C expression vector (lane 4). (E) The putative
MEF2C binding site (5 -AAAAAAAATC-3 ) of the CRT
promoter (CPF) plasmid was mutagenized to 5 -CCG-
GAATTCC-3 , a sequence not recognized by MEF2C.
NIH3T3 cells were transiently transfected with wild-type
CPF and mutated CPF, and then stimulated with bradyki-
nin. Control value for luciferase/ -galactosidase was
1009812   10%. Data shown are means   SD of four
independent experiments. Black bars denote the location
of the putative MEF2C sites; X indicates the location of
mutated MEF2C site. (F) Hearts from transgenic mice
overexpressing MEF2C. (left) Hearts from 2-mo-old wild-
type (wt) and MEF2C overexpresser (MEF2C TG) mice.
(right) Western blot analysis of protein extracts from wild-type (wt) and MEF2C (MEF2C TG) overexpresser hearts probed with anti-CRT, anti-MEF2C, and
anti-GAPDH. The bottom protein band detected by the anti-CRT antibodies corresponds to CRT degradation product. (G) MEF2C activates expression of the
luciferase reporter gene under control of the CRT promoter in wild-type mouse embryonic fibroblasts. Addition of a Ca
2  ionophore or expression of activated
CaN further enhances transcriptional activation by MEF2C. Expression of activated CaMKII had no effect on MEF2C function (luciferase/ -galactosidase  
1834875   7%). The data shown are the mean   SD of three independent experiments. (H) In crt
 /  cells, MEF2C did not activate the reporter gene.
Transcriptional activation by MEF2C was restored by treatment with a Ca
2  ionophore and by expression of activated CaN but not by expression of activated
CaMKII (luciferase/ -galactosidase   1358402   4%). The data shown are the mean   SD of three independent experiments.CALRETICULIN AND CARDIAC DEVELOPMENT • LYNCH ET AL. 43
were transfected with an expression vector encoding His-tagged
MEF2C, and MEF2C-DNA complexes were then immunopre-
cipitated with anti-His antibodies. Fig. 5 D (lane 3) shows that
the immunoprecipitate contained a DNA fragment correspond-
ing to the MEF2C binding site in the CRT promoter. Site-spe-
cific mutation of the nucleotide sequences corresponding to this
binding site inhibited MEF2C-dependent activation of the CRT
promoter (Fig. 5 E). Together these data indicate that MEF2C
binds to the CRT promoter in living cells, fibroblasts, and car-
diomyocytes and identifies a MEF2C binding site in the CRT
promoter at  845 to  836. To further demonstrate that MEF2C
activates the CRT gene, we investigated expression of CRT in
transgenic mice overexpressing MEF2C in the heart. The
MEF2C transgenic line used in this study expressed  50%
more cardiac MEF2C compared with endogenous levels (Fig. 5
F; unpublished data). Western blot analysis revealed similar in-
crease in the level of CRT in MEF2C overexpresser transgenic
hearts (Fig. 5 F). Together, our in vitro and in vivo data estab-
lish that the CRT gene is a target for MEF2C.
CRT is necessary for maintenance of 
MEF2C function
We used a luciferase reporter assay, this time to determine
whether MEF2C function is compromised in the absence of
CRT. Wild-type (Fig. 5 G) and crt
 /  cells (Fig. 5 H) were
transiently transfected with an expression vector for MEF2C
and with a vector containing the luciferase gene controlled by
the CRT promoter (Fig. 5, G and H) or the luciferase gene con-
trolled by 6  MEF2C sites (Fig. S4, available at http://
www.jcb.org/cgi/content/full/jcb.200412156/DC1). In wild-
type cells, MEF2C activated the CRT promoter and this activa-
tion was enhanced by the addition of Ca
2  and by activated
CaN (Fig. 5 G). The expression of activated CaMKII had no ef-
fect (Fig. 5 G). In contrast, in crt
 /  cells, MEF2C did not acti-
vate the reporter gene (Fig. 5 H) but it was fully restored by
Ca
2  and by activated CaN (Fig. 5 H). Again, CaMKII had no
effect on MEF2C-dependent transcriptional activity (Fig. 5, G
and H). Importantly, MEF2C-dependent activation of the lu-
ciferase gene controlled by 6  MEF2C sites was sensitive to
the presence of CsA in wild-type cells, indicating involvement
of CaN in MEF2C function (Fig. S5, available at http://
www.jcb.org/cgi/content/full/jcb.200412156/DC1). These data
indicate that Ca
2 -dependent CaN phosphatase activity is es-
sential in the Ca
2 -dependent regulation of MEF2C activity.
CRT enhances MEF2C activity
Next, we asked if up-regulation of CRT expression affects
MEF2C function. To do this we used the HEK293 Tet-On
CRT-inducible cell line (Arnaudeau et al., 2002). Cells were
transiently transfected with vector encoding luciferase reporter
gene under control of 6  MEF2C binding sites. The cells were
treated with doxycycline to induce expression of CRT followed
by luciferase reporter assay. CRT expression was doubled after
24 h of doxycycline treatment of HEK293 Tet-ON CRT cells
(Fig. 6; Arnaudeau et al., 2002). Reporter gene analysis of
bradykinin-stimulated cells revealed that HEK293 Tet-ON
CRT cells overexpressing CRT had increased activity of
MEF2C (Fig. 6). This increased activity of MEF2C was inhib-
ited by CsA (unpublished data), supporting our conclusion that
CRT affected transcriptional activity of MEF2C via the CaN-
dependent pathway. Together, these findings indicate that the
CRT gene is an important target for MEF2C and that increased
expression of CRT enhances MEF2C transcriptional activity.
Discussion
In this study, we have shown that both translocation of MEF2C
into the nucleus and transcriptional activation by MEF2C are
compromised in the absence of CRT. These conclusions are
supported by data from DNA arrays; from immunocytochemi-
cal localization of MEF2C, and GFP-MEF2C, in CRT-defi-
cient fibroblasts, in crt
 /  cardiomyocytes in culture, and in the
embryonic heart; and from RT-PCR showing reduced expres-
sion of known MEF2C target genes in embryonic hearts. The
translocation of MEF2C and its activation of transcription are
restored in CRT-deficient cells by the expression of CRT,
Ca
2 -dependent activation of CaN, and activated CaN. These
effects of CRT on MEF2C are specific to this protein because
nuclear targeting of the transcription factors MEF2A and
MEF2D, MyoD, and GATA6 is unaffected in the absence of
CRT, indicating that the nuclear translocation machinery is still
functional.
The transcription factor MEF2C plays an important role
in the control of cardiac and skeletal muscle development
(McKinsey et al., 2002; Frey and Olson, 2003). MEF2C is the
first of the MEF2 family of genes to be expressed during car-
diac development, with transcripts appearing in mesodermal
Figure 6. CRT enhances MEF2C transcriptional activity. HEK293 and
HEK293 Tet-ON CRT cells (Arnaudeau et al., 2002) were transiently
transfected with an expression plasmid for luciferase reporter gene under
control of 6  MEF2C binding sites and pSVL -galactosidase as described
in Materials and methods. Expression of CRT was induced by incubation
with doxycycline for the indicated time (Arnaudeau et al., 2002) and cells
were stimulated with bradykinin. (A) Western blot analysis of CRT level in
HEK293 and HEK293 Tet-ON cells. (B) 6  MEF2C-luciferase reporter
gene activity in HEK293 and HEK293 Tet-ON cells treated with doxycy-
cline for the indicated time. Luciferase/ -galactosidase in HEK293 and
HEK293 Tet-ON cells were 6688968   7 and 6914522   7%, re-
spectively. Data shown are means   SD of three separate experiments
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precursor cells that give rise to the heart (Lin et al., 1997; Black
and Olson, 1998). MEF2C plays a key role in the activation of
several fetal cardiac genes (Morin et al., 2000), and we found
that in the absence of CRT there is no significant expression of
MLC2v, eHAND, and Irx4, indicating that transcriptional acti-
vation by MEF2C requires CRT. DNA arrays and immunolo-
calization studies have shown that localization to the nucleus of
both NF-AT and MEF2C is impaired in the absence of CRT.
Because localization of MEF2C to the nucleus was restored by
increased cytoplasmic Ca
2  concentrations, we sought to iden-
tify which Ca
2 -dependent cytoplasmic enzymes could influ-
ence MEF2C localization and/or activity. Studies monitoring
nuclear localization and expression of the luciferase reporter
gene suggest that MEF2C function is enhanced by coexpres-
sion of activated CaN, but that it is not influenced by coexpres-
sion of activated CaMKI or activated CaMKII. Some syner-
gism among MEF2C, activated CaN, and activated CaMKIV
has previously been reported in skeletal muscle (Wu et al.,
2000), but in this study activated CaMKI and activated
CaMKII had no effect. CaMK-dependent activation of MEF2C
has been reported to occur indirectly, mainly through the phos-
phorylation of transcriptional repressors (HDACs; McKinsey
et al., 2000).
CaN is a highly conserved, Ca
2 /calmodulin-dependent
serine/threonine phosphatase (Aramburu et al., 2000), and its
role in the NF-AT signaling pathway in many tissues is well es-
tablished (Crabtree, 2001). This pathway plays a role in normal
cardiac physiology and in cardiac pathology (Molkentin et al.,
1998; Wilkins and Molkentin, 2002). For example, NF-ATc1–
deficient mice die in utero from impaired development of car-
diac valves and septa (delaPompa et al., 1998; Ranger et al.,
1998). Further, the overexpression of constitutively active
forms of either NF-ATc4 or CaN in the heart leads to severe
cardiac hypertrophy (Molkentin et al., 1998). In addition, a
mouse lacking both NF-ATc3 and NF-ATc4 die in utero from a
failure in vascular patterning, implicating CaN in vascular de-
velopment (Graef et al., 2001). MEF2C has previously been
suggested to be a substrate for CaN in hypertrophic hearts in
vivo (Passier et al., 2000). Cyclosporin, a CaN inhibitor, affects
fetal heart development in rats (Brown et al., 1985), Xenopus
laevis  (Yoshida et al., 2004), and chicken (Liberatore and
Yutzey, 2004). CaN–NF-AT pathway is also a component of
Wnt/Ca
2  signaling that plays a role in X. laevis organogenesis,
including cardiac development (Saneyoshi et al., 2002). Col-
lectively, these findings support our current observations,
which demonstrate that CaN affects cardiac development in the
mouse via a direct effect on MEF2C.
Several lines of evidence indicate that CRT is a cardiac
embryonic gene (Mesaeli et al., 1999; Guo et al., 2001; Naka-
mura et al., 2001a; Li et al., 2002). In particular, targeted disrup-
tion of the CRT gene leads to embryonic lethality at E12.5 from
impaired myofibrillogenesis and ventricular formation (Mesaeli
et al., 1999; Li et al., 2002), indicating an essential role for CRT
in the differentiation of myocardial cells. Targeted disruption of
the MEF2C gene also results in impaired formation of the right
ventricle during embryogenesis (Lin et al., 1997). More impor-
tantly, several cardiac genes are down-regulated in MEF2C-
deficient mice, indicating that MEF2C plays an essential role in
cardiac differentiation. Mice that are deficient in CRT exhibit a
cardiac phenotype very similar to that of the MEF2C gene mu-
tant (Mesaeli et al., 1999). The reason for this similarity appears
to be that CRT is an “upstream moderator” of CaN function; no-
tably, the embryonic lethality seen in CRT-deficient mice is res-
cued by cardiac-specific expression of activated CaN (Guo et
al., 2002). Ca
2  release from the ER is compromised in the ab-
sence of CRT, and it appears that this prevents proper activation
of CaN during cardiac development. The phosphatase activity
of activated CaN is not affected by the absence of CRT (Guo et
al., 2002), confirming that the activation of CaN occurs down-
stream of any effects exerted by CRT. Here we show that trans-
location of MEF2C to the nucleus fails in the absence of CRT,
both in vitro and in vivo, in fibroblasts and cardiomyocytes in
culture and in embryonic cardiomyocytes. However, the trans-
location and function of MEF2C are both restored by the activa-
tion of CaN, which likely dephosphorylates MEF2C near the
NLS, thereby allowing proper translocation of the transcription
factor into the nucleus. MEF2C nuclear targeting is also inhib-
ited in wild-type cells treated with cyclosporin, an inhibitor of
CaN phosphates activity, further supporting our conclusions
that CaN plays critical role in nuclear translocation of MEF2C
in cardiomyocytes.
Fig. 7 illustrates the interactions among CRT, Ca
2 , CaN,
and MEF2C, which have been demonstrated in the present
study. Changes in cytosolic Ca
2  concentration affect numer-
ous signal transduction pathways and influence a wide range of
Figure 7. A model of the Ca
2 -dependent signaling cascade from the ER
to the nucleus. The model shows cross talk between CRT, Ca
2 , CaN, and
MEF2C. CRT is a Ca
2 -buffering ER protein that affects Ca
2  storage in
the ER, Ca
2  release from the ER, and store-operated Ca
2  influx. Ca
2  is
released from the ER resulting in a sustained increase in intracellular Ca
2 
concentration to activate CaN. This results in dephosphorylation of the
COOH-terminal region of MEF2C, promoting its translocation to the nucleus.
In the absence of CRT, agonist-dependent Ca
2  release from the ER is in-
hibited, CaN is not activated, and MEF2C is not translocated into the
nucleus efficiently. The CRT gene is itself one of the MEF2C target genes
and up-regulation of CRT enhances MEF2C function.CALRETICULIN AND CARDIAC DEVELOPMENT • LYNCH ET AL. 45
cell and organ functions, including cardiogenesis (Webb and
Miller, 2003). To activate Ca
2 -dependent signaling pathways,
Ca
2  is released from the ER and comes from the extracellular
space leading to increase in cytoplasmic Ca
2  concentration af-
fecting multiple Ca
2 -dependent processes (Berridge et al.,
2003). During cardiac development an important target protein
is CaN (Fig. 7), which, when activated by a sustained increase
in intracellular Ca
2  concentration, dephosphorylates MEF2C,
promoting its translocation from the cytoplasm into the nucleus
(Fig. 7). Among its many effects, Ca
2  release from the ER
also activates CaMKs. These kinases are known to influence
MEF2C function in the heart via phosphorylation of a specific
HDAC (McKinsey et al., 2001), which promotes HDAC nu-
clear export. In the absence of CRT, agonist-dependent Ca
2 
release from the ER is inhibited (Nakamura et al., 2001b) and,
as a result, CaN is not fully activated and MEF2C is not trans-
located into the nucleus efficiently (Li et al., 2002). In human
T-lymphocytes CaN is a downstream molecule of the InsP3 re-
ceptor in cell growth and apoptotic pathways (Jayaraman and
Marks, 2000), providing additional support for the role of ER
in CaN-dependent pathways.
One of the most interesting findings in the present study
is that the CRT gene is itself a target for transcriptional activa-
tion by MEF2C in developing cardiac muscle. Using ChIP
analysis, we found that MEF2C binds to the CRT promoter in
vivo. Most importantly, up-regulation of CRT expression has a
significant positive effect on MEF2C transcriptional activity,
illustrating a positive feedback mechanism whereby MEF2C
controls the expression of an ER Ca
2 -binding protein to en-
sure a sufficient supply of “releasable” Ca
2  for its own activa-
tion, via CaN (Fig. 7). Importantly, this positive feedback path-
way also ensures that the Ca
2 -dependent activity of MEF2C is
preserved. Rosenberg et al. (2004) reported that function of
NF-AT is regulated by neuromuscular stimulation in skeletal
muscle and that Ca
2  entry via TRPC3 channel is critical for
this activity. Interestingly, expression of TRPC3 in skeletal
muscle is up-regulated by the CaN/NFAT-dependent pathway
(Rosenberg et al., 2004). A positive feedback mechanism be-
tween MEF2C, CRT, and CaN in the heart may also exist
between NF-AT, TRPC3, and CaN in skeletal muscle. In con-
clusion, the present findings identify important functional
relationships between CRT, CaN, and MEF2C in the early
stages of cardiac development in vivo, and they indicate that
the failure of these interactions is a major cause of the embry-
onic lethality in CRT-deficient mice. Other CaN-dependent
pathways including activation of NF-AT may also contribute to
the embryonic lethality observed in the absence of CRT (Me-
saeli et al., 1999).
In vertebrates, expression of MEF2C in the heart occurs
very early on in development, at E7.5 (Lints et al., 1993; Ed-
mondson et al., 1994; Molkentin et al., 1996). At E9.5 the ex-
pression of MEF2C is observed throughout the cardiac atria
and ventricles, and it continues to be highly expressed until
E14.5. This pattern of expression is highly similar to that ob-
served for CRT in the developing myocardium (Mesaeli et al.,
1999). Further, after birth there is a parallel decline in the car-
diac expression of both MEF2C and CRT, and, conversely,
during cardiac hypertrophy in adults both genes are up-regu-
lated (Edmondson et al., 1994). This last observation indicates
that MEF2C-dependent activation of the CRT gene, and CRT/
CaN-dependent functional regulation of MEF2C, may also
play an important role in adult cardiac pathology.
The CRT gene is a target for the transcription factors
Nkx2.5 (Guo et al., 2001) and myocardin, which are expressed
as early as E7.5 in the embryonic heart. Therefore, the se-
quence of events during cardiac development seems to be a
very early activation of the CRT gene, by Nkx2.5 and other
cardiac-specific transcription factors, followed by the expres-
sion of MEF2C at E9.5 and the subsequent activation of several
cardiac-specific genes, including the CRT gene. The CRT gene
is an extremely important target for MEF2C because, at these
stages in cardiac development, CRT plays a critical role in en-
abling MEF2C to function. In summary, the data presented
here identify an important role for CRT and CaN in transduc-
tion of the Ca
2  signaling pathways, which activate the tran-
scription factor MEF2C in the developing myocardium. They
also highlight a previously unrecognized positive feedback
loop, whereby CRT modulates MEF2C activity and MEF2C
regulates the expression of CRT.
Materials and methods
Plasmid DNA
Expression vectors containing cDNA encoding MEF2C, GFP-HDAC5, acti-
vated CaN, and activated CaMKI were obtained from E.N. Olson (Univer-
sity of Texas Southwestern Medical Center, Dallas, TX); MEF2A and MEF2D
cDNAs from J. McDermott (York University, Toronto, Canada); Nkx2.5 from
I. Komuro (University of Tokyo, Tokyo, Japan); GATA6 from M. Nemer
(Institut de Recherches Cliniques de Montreal, Montreal, Canada); NF-ATc4
from T. Hoey (Tularik, San Francisco, CA); MyoD from M. Puceat (Centre
National de la Recherche Scientifique, Montpellier, France); and activated
CaMKII from H. Schulman (Stanford University, Stanford, CA).
To generate a MEF2C expression vector (pcDNA-MEF2C-myc-His), a
cDNA fragment encoding 432 aa residues of mouse MEF2C was amplified
by a PCR-driven reaction and cloned into the XhoI and BamHI sites of
pcDNA3.1/myc-His. cDNAs encoding full-length or parts of proteins were
generated by PCR-driven reaction and subcloned into the pEGFP-C1 expres-
sion vector to generate GFP fusion proteins; construction of GFP-NF-ATc4
has been described previously (Guo et al., 2002). Full-length MEF2C cDNA
was cloned into the XhoI and HindIII sites of pEGFP-C1 plasmid to generate
GFP-MEF2C expression vector; the full-length MEF2A cDNA was cloned
into the XhoI and EcoRI sites of pEGFP-C1 to create GFP-MEF2A; the MyoD
cDNA was cloned into EcoRI and XbaI sites of pEGFP-C1 to create GFP-
MyoD; the MEF2C-NRS-NLS cDNA encoding the COOH-terminal region
was cloned into the XhoI and BamHI sites of pEGFP-C1; a MEF2C-NLS en-
coding DNA was made synthetically and cloned into the XhoI and sites of
pEGFP-C1 plasmid; the NLS region of GATA6 was isolated by SstI and
EcoRI digestion of GATA6 cDNA and then cloned into the pEGFP-C1 vector
to generate a pGFP-GATA6-NLS expression vector.
DNA array and RT-PCR analyses
Cells were transiently transfected with pcDNA-MEF2C-myc-His expression
vector using FuGENE 6 system and treated with bradykinin to induce
InsP3-dependent Ca
2  release from the ER before harvesting (Nakamura et
al., 2001b). crt
 /  fibroblasts were also treated with 1  M ionomycin for
4.5 h before harvesting. The nuclear proteins were isolated and then ap-
plied to TranSignal protein/DNA arrays (Panomics Inc.).
RNA was isolated from E12.5 wild-type and crt
 /  embryos fol-
lowed by cDNA synthesis (Li et al., 2002). cDNA products were analyzed
by step-down PCR using the following primers: for MLC2v, 5 -CCCA-
GATCCAGGAGTTCAAGGAAGC-3  forward and 5 -GGTCAGCATCTC-
CCGGACATAGTC-3  reverse primers; for eHAND (GenBank/EMBL/
DDBJ accession no. S79216), 5 -CCGCCGCACCCCATGCTCCACG-3 
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for Irx4, 5 -GGCAGCTCGCAGGGCTATGG-3  forward and 5 -
GGCGTCTTCAGCTCACATTCTG-3  reverse primers. GATA6 RT-PCR
analysis was performed as a control using the forward 5 -GAGTGGAG-
GTGGCGGCAGCCTG-3  and reverse 5 -GAGCCACTGCTGTTACCG-
GAGC-3  primers.
Western blotting and immunohistochemistry
For quantitative analysis of nuclear and cytoplasmic distribution of GFP-
MEF2C, wild-type and crt
 /  mouse embryonic fibroblasts were transiently
transfected with plasmid DNA containing cDNA encoding MEF2C,
treated with bradykinin (Nakamura et al., 2001b), and harvested. Cyto-
plasmic and nuclear proteins were isolated 48 h after transfection using
an extraction kit (Panomics Inc.). Protein extracts (30  g) were loaded
onto a 10% SDS-PAGE gel, transferred to nitrocellulose membranes, and
blotted with polyclonal goat anti-GFP (1:5,000; a gift from L. Berthiaume,
University of Alberta, Edmonton, Alberta, Canada) followed by a peroxi-
dase-conjugated rabbit anti–goat secondary antibody (1:10,000). Immu-
nocytochemistry of cultured cells and mouse embryos was performed as
described previously (Mesaeli et al., 1999). Polyclonal rabbit anti-MEF2C
(Cell Signaling) was used at 1:70 dilution followed by a donkey anti–rab-
bit Texas red (1:70). Dephosphorylation analysis of MEF2C was per-
formed (Wu et al., 2000) using crt
 /  fibroblasts transiently cotransfected
with expression vectors encoding activated CaN and GFP-MEF2C-NRS-
NLS or GFP-MEF2C-NLS. Western blot analysis was performed with goat
anti-GFP antibodies (1:5,000). Mouse mAb to glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) was used at 1:2,000. In some experi-
ments, wild-type cells were treated for 60 min with CsA (0.1  M) or with
CaMK inhibitor KN-62 (1  M).
CRT promoter, EMSA, and ChIP analysis
For mutation and deletion analysis, a plasmid containing the CRT pro-
moter (CPF) in front of luciferase reporter gene was used (Waser et al.,
1997). The MEF2C binding site in the CRT promoter was changed from
5 -AAAAAAAATC-3  (nt  845 to  836) to 5 -CCGGAATTCC-3 . Lu-
ciferase and  -galactosidase activity assays were performed as described
previously (Waser et al., 1997). A plasmid containing 6  MEF2C DNA
binding sites upstream of a minimal promoter and a luciferase reporter
gene was also used in this study.
For ChIP analysis, wild-type mouse embryonic fibroblasts and neo-
natal cardiomyocytes from hearts of 5-d-old neonatal rats were used (Guo
et al., 2001). Cells were transiently transfected with pcDNA-MEF2C myc-
His vector, fixed in 1% formaldehyde at RT for 20 min, and lysed. Chro-
matin was sheared by sonication and precleared extracts were incubated
at 4 C for 3 h with mouse anti-His mAbs (1:150). The coimmunoprecipi-
tated DNA was purified and analyzed by Touch-down PCR using the fol-
lowing primers: 5 -CCCTTGCCTTCTGCCGTTTATTG-3  forward and 5 -
CCCGTAGTTCCCTGCAGCCTGT-3  reverse.
For EMSA, MEF2C and luciferase proteins were synthesized using
a coupled transcription and translation reticulocyte system (Guo et al.,
2001). Synthetic oligodeoxynucleotides corresponding to the  845 to
 836 nucleotide sequence (5 -GAGAAAGAGAAAAAAAAAAAATCAA-
AAAACCCC-3 ; Probe 1) of the putative MEF2C binding site in the CRT
promoter and a derivative of this sequence (5 -GAGAAAGAGAAAA-
CTAAAAATAAAAAAAACCCC-3 ; Probe 2) containing an idealized
MEF2C element were used.
Analysis of MEF2C mutants
Site-specific mutagenesis of MEF2C COOH-terminal serine or threonine
residues was carried by a PCR-driven amplification of cDNA encoding
MEF2C (Guo et al., 2003). Mutated PCR product was cloned into pEGFP-C1.
Identical 5  primer was used for all reactions (5 -CCGCTCGAGCAATGG-
GGAGAAAAAAGATTCAGATTACG-3 ). The following 3  primers were
used: for T409A mutation, 5 -CCCAAGCTTTCATGTTGCCCATCCTTC-
AGAGAGTCGCATGCGCTTGACTGAAGGACTTTCCCTTTCGTCCGGC-
GAAGGTCTGGCGAGTCCAATG-3 ; for S412A mutation, 5 -CCCAA-
GCTTTCATGTTGCCCATCCTTCAGAGAGTCGCATGCGCTTGACTGAA-
GGACTTTCCCTTTCGTCCGGCGCAGGTC-3 ; for S418A mutation, 5 -
CCCAAGCTTTCATGTTGCCCATCCTTCAGAGAGTCGCATGCGCTTGA-
CTGAAGGAGCTTCCCTTTC-3 ; for S420A mutation, 5 -CCCAAG-
CTTTCATGTTGCCCATCCTTCAGAGAGTCGCATGCGCTTGACTGCAG-
GACTTTC-3 ; for S427A mutation, 5 -CCCAAGCTTTCATGTTGCCCATC-
CTTCAGCGAGTCG-3 ; for T432A mutation, 5 -CCCAAGCTTTCATGC-
TGCCCATCCTTCAGAG-3 . Underlined is the location of the mutagenized
codons. Cells were transiently cotransfected with plasmids DNA,  -galac-
tosidase, and a plasmid encoding luciferase reporter gene under control
of 6  MEF2C-specific sites.
MEF2C activity in CRT-inducible HEK293 cells
HEK293 and HEK293 Tet-ON CRT cells, inducible with respect to full-
length mature CRT expression (Arnaudeau et al., 2002), were transiently
cotransfected with expression vector encoding MEF2C and a vector con-
taining promoter luciferase reporter gene under control of 6  MEF2C.
CRT expression was induced by doxycycline (Arnaudeau et al., 2002).
Cells were harvested followed by luciferase and  -galactosidase activity
assays (Waser et al., 1997).
Miscellaneous
The cDNA-encoding mouse MEF2C was cloned in the  -myosin heavy
chain promoter containing vector (a gift from J. Robbins, Children’s Hospi-
tal Medical Center of Cincinnati, Cincinnati, OH) by blunt end ligation.
The vector was digested and a fragment containing the promoter and
cDNA fusion was purified for injection in to newly fertilized oocytes for the
standard generation of transgenic mice. Mouse mAb to GAPDH was pur-
chased from Ambion and was used at a concentration of 1:2,000. Sec-
ondary antibody was rabbit anti–mouse HRP at a dilution of 1:2,000.
NIH3T3 fibroblasts, wild-type embryonic fibroblasts, and CRT-deficient
embryonic fibroblasts were maintained as described previously (Naka-
mura et al., 2001b). HEK293 and HEK2993 Tet-ON CRT cells were cul-
tured as previously described (Arnaudeau et al., 2002). Primary car-
diomyocyte cultures were obtained from day 12.5 mouse embryos as
described previously (Guo et al., 2001). Protein concentration was mea-
sured as described previously (Bradford, 1976). Mouse genotyping was
performed by a PCR-driven amplification of genomic DNA (Guo et al.,
2002). All images were examined with a microscope (model Axiovert
S100; Carl Zeiss MicroImaging, Inc.), captured, and pseudocolored in
Northern Eclipse 5.0 software. cDNA nucleotide sequences were con-
firmed by nucleotide sequence analysis performed at the DNA Core Facil-
ity at the Department of Biochemistry, University of Alberta.
Online supplemental material
Fig. S1 shows immunocytochemical analysis of MEF2C and GFP-MEF2C in
wild-type and crt
 /  cells expressing activated CaMKI. Fig. S2 shows intra-
cellular localization of GFP-HDAC5 in wild-type and crt
 /  cells expressing
activated CaN and activated CaMKII. Fig. S3 shows activation of the CRT
promoter by MEF2C. Fig. S4 shows effects of CRT on MEF2C function in
wild-type and crt
 /  mouse embryonic fibroblasts. Fig. S5 shows an effect
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http://www.jcb.org/cgi/content/full/jcb.200412156/DC1.
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